Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca PLC

www.astrazeneca.com

Latest From AstraZeneca PLC

Market Brief: New Triple-Combination Therapies Help Boost Lackluster Inhalation Devices Market

The inhalation devices market will reach $12bn by 2023, driven by the rising prevalence of asthma and COPD worldwide. GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim dominate worldwide sales of inhaled asthma and COPD devices, and are facing generic competition. Generics developers and the major pharma players are trying to set themselves apart with better drug-delivery products. 

Market Intelligence Respiratory

Vaccine Development Challenges Include Extensive Quality Control, Sanofi's Loew Notes

Sanofi spends 70% of vaccine production on quality control, Sanofi Pasteur exec VP David Loew tells the Pink Sheet; company is working on next generation flu vaccines that may provide greater efficacy.

Vaccines Research & Development

EU Approvals: J&J's Darzalex Steps Ahead With New Indication

The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two first-line additional indications, in multiple myeloma and head and neck cancer, respectively.

 

 

ImmunoOncology Approvals

Five Companies To Watch At The Jefferies Conference

Novartis and Roche will present alongside up-and-coming biotechs and microcaps.

Companies Leadership
See All

Company Information

UsernamePublicRestriction

Register